An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer
This observational study will investigate the tolerability and efficacy of Tarceva (erlotinib) in daily clinical practice under routine conditions in patients with locally advanced or metastatic non small cell lung cancer. Data will be collected for approximately 12 months.
Non-Squamous Non-Small Cell Lung Cancer
Overall survival at 1 year, 12 months
Tolerability of Tarceva in daily clinical practice under routine conditions, 12 months|Efficacy of Tarceva in daily clinical practice under routine conditions, 12 months|Reproducibility of the results of the controlled SATURN study, 12 months
This observational study will investigate the tolerability and efficacy of Tarceva (erlotinib) in daily clinical practice under routine conditions in patients with locally advanced or metastatic non small cell lung cancer. Data will be collected for approximately 12 months.